B-Cell Non-Hodgkin's Lymphoma: What It Is, Subtypes, and Treatment Landscape

What Is B-Cell Non-Hodgkin's Lymphoma?

B-cell non-Hodgkin's lymphoma is a cancer that originates in B lymphocytes, a type of white blood cell responsible for producing antibodies. Instead of dying at the end of their normal life cycle, these B cells grow uncontrollably and accumulate in lymph nodes and other organs. Non-Hodgkin's lymphoma as a whole is more common than Hodgkin lymphoma, and B-cell subtypes account for roughly 85 to 90 percent of all NHL cases. The disease can be indolent, meaning it grows slowly and may not require immediate treatment, or aggressive, requiring prompt therapy.

Common Subtypes of B-Cell NHL

B-cell non-Hodgkin's lymphoma is not a single disease but a group of related cancers. The most frequently encountered subtypes include:

• Diffuse Large B-Cell Lymphoma (DLBCL): The most common aggressive subtype, accounting for about 30 to 40 percent of all NHL cases. It often presents as a rapidly growing mass.
• Follicular Lymphoma: The second most common subtype, typically indolent, characterized by a follicular growth pattern. Many patients live for years with this disease, though it can transform into a more aggressive form.
• Mantle Cell Lymphoma: An aggressive subtype that often involves the lymph nodes, bone marrow, and spleen at diagnosis. It carries a distinct genetic marker involving the cyclin D1 gene.
• Burkitt Lymphoma: A highly aggressive but potentially curable lymphoma, more common in children and young adults, often associated with specific chromosomal translocations.
• Marginal Zone Lymphoma: A slower-growing group that includes mucosa-associated lymphoid tissue (MALT) lymphoma, often linked to chronic infections like H. pylori.
• Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Considered the same disease in different phases, it primarily affects older adults and involves the blood, bone marrow, and lymph nodes.

Symptoms and Diagnosis

The most common first sign of B-cell non-Hodgkin's lymphoma is a painless swelling of lymph nodes in the neck, armpit, or groin. Other symptoms can include unexplained fever, night sweats, weight loss (often called B symptoms), fatigue, and itching. Diagnosis typically begins with a physical exam and blood tests, followed by a lymph node biopsy, which is the definitive test. The biopsy is examined under a microscope and tested for specific markers using immunohistochemistry and flow cytometry to identify the exact subtype. Additional imaging such as CT, PET, or MRI scans helps determine how far the disease has spread, a process called staging.

Staging and Prognosis

Staging ranges from stage I, where the disease is confined to a single lymph node region, to stage IV, where it has spread widely to organs like the liver or bone marrow. The prognosis depends heavily on the subtype, the stage at diagnosis, the patient's age, and overall health. Doctors also use prognostic scores like the International Prognostic Index for aggressive lymphomas or specific markers for indolent types to guide expectations.

Treatment Options

Treatment is tailored to the specific subtype and stage. Common approaches include:

• Watchful Waiting: For indolent subtypes without symptoms, active monitoring may be preferred over immediate treatment.
• Chemotherapy: Regimens like R-CHOP, which combines rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone, remain a backbone for aggressive B-cell lymphomas.
• Immunotherapy: Monoclonal antibodies such as rituximab and obinutuzumab target CD20 on B cells. Newer agents include bispecific antibodies and CAR T-cell therapy, which engineers a patient's own T cells to attack lymphoma cells.
• Radiation Therapy: Often used for early-stage localized disease or to shrink symptomatic masses.
• Targeted Therapy: Drugs like ibrutinib, venetoclax, and lenalidomide are used for specific subtypes or relapsed disease.
• Stem Cell Transplant: High-dose chemotherapy followed by autologous stem cell rescue may be an option for eligible patients with relapsed or refractory disease.

Living With B-Cell Non-Hodgkin's Lymphoma

A diagnosis of B-cell non-Hodgkin's lymphoma can be overwhelming, but outcomes have improved significantly over the past two decades, especially for DLBCL, which is now considered potentially curable in a majority of cases. For indolent subtypes, the goal is often long-term disease management rather than cure. Patients benefit from a multidisciplinary care team that includes a hematologist-oncologist, pathologist, radiologist, and supportive care specialists. Regular follow-up, monitoring for transformation to a more aggressive lymphoma, and attention to long-term side effects of treatment are key parts of living well with this disease.